Biologically Effective Dose-response Relationship for Patients with Limited-stage Small-cell Lung Cancer Treated with Combined Radiotherapy and Chemotherapy

B. Xia,G. Y. Chen,X. W. Cai,J. D. Zhao,M. Fan,H. J. Yang,K. L. Zhao,X. L. Fu

DOI: https://doi.org/10.1016/j.ijrobp.2010.07.1203

2010-01-01

Abstract:Although multiple studies have confirmed the value of thoracic radiation therapy (RT) in limited-stage small-cell lung cancer (LS-SCLC), the appropriate RT dose remains controversial. This study aimed to evaluate the correlation between the biologically effective RT dose and local tumor control and overall survival for patients with LS-SCLC. The medical records of 205 LS-SCLC patients treated with radical RT (≥50 Gy) and combined chemotherapy at the Fudan University Cancer Hospital between 1997 and 2006 were retrospectively reviewed. Biologically effective dose (BED) was calculated for RT dose homogenization. Patients were grouped by BED (≤57 Gy and >57 Gy, 57 Gy equivalent to 60 Gy in 30 fractions in 6 weeks). Treatment interruption during RT was used as the “marker” for treatment toxicity. Kaplan-Meier analysis was used to calculate overall survival (OS), progression-free survival (PFS), local control rate (LCR), and distant-metastasis-free survival (DMFS) for both groups of patients. Of the 205 patients, 70 had received ≤57 Gy (lower BED group) and 135 >57 Gy (higher BED group). The patient and treatment characteristics were similar in the two groups except for the daily fractions, twice-daily RT was significantly more frequent in the higher BED group (p = 0.000). RT interruptions were recorded in 46 cases (22%), with a median duration of 6 days (range, 1-18). No differences in treatment-related toxicity rates were demonstrated between the two BED groups (p = 0.339).The median follow-up time was 20.7 months (range, 3.6-102.8 months) for all analyzable patients and 50.8 months (range, 27.3-102.8 months) for patients alive. The LCR and DMFS at 2 years for the higher and lower BED groups were 83.7% and 62.5% (p = 0.024) and 55.7% and 43.0% (p = 0.196), respectively. Patients in the higher BED group had a statistically significant better 5 years OS (26.2% vs. 14.6%, p = 0.005) and PFS (19.4% vs. 12.9%, p = 0.006). There were no significant difference for OS between the once-daily and twice-daily groups (p = 0.575). Multivariable Cox regression model demonstrated that age (p = 0.004), Karnofsky performance status (p = 0.005), weight loss < 5% (p = 0.032), and BED (p = 0.043) were significant predictors of OS. This study has shown that patients treated with BED > 57 Gy have better LCR, PFS and OS compared those treated with BED ≤ 57 Gy, indicating that a positive BED-response relationship still exist even though in a scope of relatively high BED. Future studies are warranted to examine the optimal RT doses and fractionation to achieve the appropriate BED for LS-SCLC, especially with modern RT techniques.